Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions.
1/5 보강
[BACKGROUND] It has been shown that neopterin levels in various body fluids can help predict the diagnosis of different malignancies.
- p-value p < 0.05
- p-value p < 0.0001
APA
Icer MA, Koçak T, et al. (2025). Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions.. BMC cancer, 25(1), 1395. https://doi.org/10.1186/s12885-025-14300-y
MLA
Icer MA, et al.. "Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions.." BMC cancer, vol. 25, no. 1, 2025, pp. 1395.
PMID
40877809 ↗
Abstract 한글 요약
[BACKGROUND] It has been shown that neopterin levels in various body fluids can help predict the diagnosis of different malignancies. Although many studies have investigated the roles of serum neopterin concentrations, tryptophan metabolism, and the dietary inflammation index (DII) in various cancers, the connection between these factors and prostate cancer (PC) remains uncertain. The aim of this study was to investigate the predictive and prognostic roles of serum neopterin, and kynurenine levels, along with the kynurenine-to-tryptophan ratio (KTR) and DII in prostate cancer.
[METHODS] This study was conducted with 57 newly diagnosed prostate cancer patients, 55 benign prostate hyperplasia patients, and 56 healthy male individuals in the control group, all aged 40 years and older. Participants had specific anthropometric measurements taken, and three-day food records were kept. DII was calculated based on data for thirty-four available nutrients by using food records. Serum levels of neopterin, kynurenine, tryptophan, tumor necrosis factor alpha (TNF-α), and interferon-gamma (IFN-γ) were measured using an enzyme-linked immunosorbent assay (ELISA) method.
[RESULTS] Serum neopterin (11.79 ± 6.09), kynurenine (1655.48 ± 1122.04), TNF-α (221.59 ± 232.06) and IFN-γ (137.68 ± 107.11) levels were higher in the malignant group than in both the control (2.72 ± 0.76, 352.40 ± 69.33, 223.94 ± 226.67, and 23.03 ± 7.28, respectively) and benign groups (3.17 ± 0.74, 377.94 ± 109.05, 179.61 ± 224.36, and 25.63 ± 7.50, respectively) (p < 0.05). Another result of our study is that in the malignant group, serum neopterin levels exhibited significant positive correlations with serum kynurenine (r = 0.80, p < 0.0001), IFN-γ (r = 0.86, p < 0.0001) and TNF-α levels (r = -0.27, p = 0.0453) and DII (r = 0.30, p = 0.0229), while they exhibited weak correlations with serum PSA, and other diet parameters. Additionally, kynurenine was the only parameter showing significant differences in mean values concerning surgical margins (p < 0.05).
[CONCLUSIONS] The findings of this study support the hypothesis that serum neopterin and specific tryptophan catabolites (e.g., kynurenine), could serve as predictive and prognostic biomarkers for prostate cancer diagnosis. However, our results do not support the hypothesis that DII and certain dietary factors play a direct role in the development or diagnosis of prostate cancer.
[METHODS] This study was conducted with 57 newly diagnosed prostate cancer patients, 55 benign prostate hyperplasia patients, and 56 healthy male individuals in the control group, all aged 40 years and older. Participants had specific anthropometric measurements taken, and three-day food records were kept. DII was calculated based on data for thirty-four available nutrients by using food records. Serum levels of neopterin, kynurenine, tryptophan, tumor necrosis factor alpha (TNF-α), and interferon-gamma (IFN-γ) were measured using an enzyme-linked immunosorbent assay (ELISA) method.
[RESULTS] Serum neopterin (11.79 ± 6.09), kynurenine (1655.48 ± 1122.04), TNF-α (221.59 ± 232.06) and IFN-γ (137.68 ± 107.11) levels were higher in the malignant group than in both the control (2.72 ± 0.76, 352.40 ± 69.33, 223.94 ± 226.67, and 23.03 ± 7.28, respectively) and benign groups (3.17 ± 0.74, 377.94 ± 109.05, 179.61 ± 224.36, and 25.63 ± 7.50, respectively) (p < 0.05). Another result of our study is that in the malignant group, serum neopterin levels exhibited significant positive correlations with serum kynurenine (r = 0.80, p < 0.0001), IFN-γ (r = 0.86, p < 0.0001) and TNF-α levels (r = -0.27, p = 0.0453) and DII (r = 0.30, p = 0.0229), while they exhibited weak correlations with serum PSA, and other diet parameters. Additionally, kynurenine was the only parameter showing significant differences in mean values concerning surgical margins (p < 0.05).
[CONCLUSIONS] The findings of this study support the hypothesis that serum neopterin and specific tryptophan catabolites (e.g., kynurenine), could serve as predictive and prognostic biomarkers for prostate cancer diagnosis. However, our results do not support the hypothesis that DII and certain dietary factors play a direct role in the development or diagnosis of prostate cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.